Literature DB >> 8402731

Scintigraphic detection of xenografted tumors producing human basic fibroblast growth factor.

H Kobayashi1, H Sakahara, M Hosono, M Shirato, J Konishi, J A Takahashi, Y Oda, H Kikuchi, K Endo, Y Kozai.   

Abstract

A murine monoclonal antibody 3H3 recognizes the basic fibroblast growth factor (FGF) and inhibits the growth of human glioblastoma cells both in vitro and in vivo. We studied the potential of a scintigraphic technique using the 3H3 antibody to detect tumors that produce basic FGF. 125I- and 111In-labeled 3H3 bound to U87MG human glioblastoma cells in vitro. U87MG cells were inoculated subcutaneously into nude mice. After development of the tumor, radiolabeled 3H3 was injected into the subcutaneous space surrounding the tumor. A high level of radioactivity from 3H3 was retained at the tumor, whereas an irrelevant antibody cleared rapidly from the injected site. Radiolabeled 3H3 was not retained in tumors that did not produce basic FGF. Scintigraphic detection of tumors expressing basic FGF would be valuable for the therapeutic application of the antibody.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402731     DOI: 10.1007/bf01518449

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  29 in total

Review 1.  Structural characterization and biological functions of fibroblast growth factor.

Authors:  D Gospodarowicz; N Ferrara; L Schweigerer; G Neufeld
Journal:  Endocr Rev       Date:  1987-05       Impact factor: 19.871

2.  Long term culture of normal and neoplastic human glia.

Authors:  J Pontén; E H Macintyre
Journal:  Acta Pathol Microbiol Scand       Date:  1968

3.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas.

Authors:  J A Takahashi; M Fukumoto; K Igarashi; Y Oda; H Kikuchi; M Hatanaka
Journal:  J Neurosurg       Date:  1992-05       Impact factor: 5.115

6.  Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma.

Authors:  J A Carrasquillo; J L Mulshine; P A Bunn; J C Reynolds; K A Foon; R W Schroff; P Perentesis; R G Steis; A M Keenan; M Horowitz
Journal:  J Nucl Med       Date:  1987-03       Impact factor: 10.057

7.  Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas.

Authors:  J F Chatal; J C Saccavini; J F Gestin; P Thédrez; C Curtet; M Kremer; D Guerreau; D Nolibé; P Fumoleau; Y Guillard
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

8.  Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase.

Authors:  H P Kalofonos; T R Pawlikowska; A Hemingway; N Courtenay-Luck; B Dhokia; D Snook; G B Sivolapenko; G R Hooker; C G McKenzie; P J Lavender
Journal:  J Nucl Med       Date:  1989-10       Impact factor: 10.057

9.  Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer.

Authors:  V M Macauly; J D Teale; M J Everard; G P Joshi; I E Smith; J L Millar
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

10.  An angiogenic growth factor is expressed in human glioma cells.

Authors:  T A Libermann; R Friesel; M Jaye; R M Lyall; B Westermark; W Drohan; A Schmidt; T Maciag; J Schlessinger
Journal:  EMBO J       Date:  1987-06       Impact factor: 11.598

View more
  3 in total

1.  In vivo anti-tumor effect of expressing p14ARF-TAT using a FGF2-targeted cationic lipid vector.

Authors:  Guoqin Niu; Wouter H P Driessen; Sean M Sullivan; Jeffrey A Hughes
Journal:  Pharm Res       Date:  2011-01-19       Impact factor: 4.200

2.  A novel immunoscintigraphy technique using metabolizable linker with angiotensin II treatment.

Authors:  Y Nakamoto; H Sakahara; T Saga; N Sato; S Zhao; Y Arano; Y Fujioka; H Saji; J Konishi
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

3.  Comparison of the chase effects of avidin, streptavidin, neutravidin, and avidin-ferritin on a radiolabeled biotinylated anti-tumor monoclonal antibody.

Authors:  H Kobayashi; H Sakahara; K Endo; M Hosono; Z S Yao; S Toyama; J Konishi
Journal:  Jpn J Cancer Res       Date:  1995-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.